HIMS puked up its Wegovy today!Hims & Hers Health
HIMS
shares were down more than 34.63% in Monday trading, while Novo Nordisk
NVO stock was down over 5% after Novo Nordisk said it has halted its collaboration with Hims & Hers on the sale of weight loss drugs, including Wegovy.
The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform.
Novo Nordisk said direct access to the drug would no longer be available through Hims & Hers Health because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
This stock failed to catch a bid despite the equity markets strong.
